Polymorphisms inCD84,IL12BandTNFAIP3are associated with response to biologics in patients with psoriasis
British Journal of Dermatology2016Vol. 176(5), pp. 1288–1296
Citations Over TimeTop 10% of 2016 papers
J.M.P.A. van den Reek, Marieke J. H. Coenen, Mariluz van de L’Isle Arias, Jeffrey Zweegers, Diana Rodijk‐Olthuis, Joost Schalkwijk, Sita H. Vermeulen, Irma Joosten, P.C.M. van de Kerkhof, Marieke M.B. Seyger, Patrick L.J.M. Zeeuwen, E.M.G.J. de Jong
Abstract
We demonstrated a strong association between etanercept use in psoriasis and variations in CD84, a gene that was previously found to be a predictor of response to etanercept in rheumatoid arthritis.
Related Papers
- → Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria(2015)40 cited
- → Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry(2015)12 cited
- → Medication adherence and persistence in the treatment of rheumatoid arthritis with adalimumab and etanercept. Six years of analysis(2014)9 cited
- → Paradoxical worsening of psoriasis when switching from etanercept to adalimumab: A case series(2010)18 cited
- → Adalimumab and etanercept adherence, persistence and switch in the treatment of psoriatic arthritis: 10-year real-life analysis(2019)8 cited